Clinical trial
A Phase I Clinical Research Study Evaluating the Safety, Tolerability and Biological Effects of the Chimeric Anti-CD40 Monoclonal Antibody Chi Lob 7/4 Given Intravenously, Weekly for Four Weeks in the Treatment of Patients With Advanced Malignancies Refractory to Conventional Anti-cancer Treatment.
NCT01561911 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Research Study Evaluating the Safety, Tolerability and Biological Effects of the Chimeric Anti-CD40 Monoclonal Antibody Chi Lob 7/4 Given Intravenously, Weekly for Four Weeks in the Treatment of Patients With Advanced Malignancies Refractory to Conventional Anti-cancer Treatment.
- Lead sponsor
- Cancer Research UK
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- October 31, 2014
- Enrollment
- 29 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.